Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Horakova, Dana ^a   Zivadinov, Robert ^b   Weinstock Guttman, Bianca ^b   Havrdova, Eva ^a   Qu, Jun ^c   Tamaño Blanco, Miriam ^c   Badgett, Darlene ^c   Tyblova, Michaela ^a   Bergsland, Niels ^b   Hussein, Sara ^b   Willis, Laura ^b   Krasensky, Jan ^a   Vaneckova, Manuela ^a   Seidl, Zdenek ^a   Lelkova, Petra ^a   Dwyer, Michael G ^b   Zhang, Ming ^c   Yu, Haoying ^c   Duan, Xiaotao ^c   Kalincik, Tomas ^d   Ramanathan, Murali ^b,c   more..

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CALCIFEDIOL; COTININE; EARLY ANTIGEN; EARLY ANTIGEN DIFFUSE; EPSTEIN BARR VIRUS ANTIGEN 1; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; OLIGOCLONAL BAND; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN;

ADULT; ARTICLE; BLOOD LEVEL; BRAIN DAMAGE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; COTININE BLOOD LEVEL; CYTOMEGALOVIRUS; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; RELAPSE; RISK FACTOR; SMOKING; VITAMIN BLOOD LEVEL;

ADULT; ANTIBODIES, VIRAL; COHORT STUDIES; CYTOMEGALOVIRUS; DISEASE PROGRESSION; ENVIRONMENT; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HLA-DRB1 CHAINS; HUMANS; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; YOUNG ADULT;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; MIRIDAE;

EID: 84872203150     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053996     Document Type: Article

References (37)

1. Ascherio A, Munger KL, (2007) Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 61: 504-513.
2. Ascherio A, Munger KL, (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61: 288-299.
3. Simon KC, van der Mei IA, Munger KL, Ponsonby A, Dickinson J, et al. (2010) Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 74: 1365-1371.
4. De Jager PL, Chibnik LB, Cui J, Reischl R, Lehr S, et al. (2009) Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurology 8: 1111-1119.
5. Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, et al. (2009) Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol 209: 123-130.
6. Zivadinov R, Zorzon M, Weinstock-Guttman B, Serafin M, Bosco A, et al. (2009) Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 80: 620-625.
7. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, et al. (2005) Cigarette smoking and the progression of multiple sclerosis. Brain 128: 1461-1465.
8. Pekmezovic T, Drulovic J, Milenkovic M, Jarebinski M, Stojsavljevic N, et al. (2006) Lifestyle factors and multiple sclerosis: A case-control study in Belgrade. Neuroepidemiology 27: 212-216.
9. Zivadinov R, Weinstock-Guttman B, Hashmi K, Abdelrahman N, Stosic M, et al. (2009) Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 73: 504-510.
10. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ (2012) Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology.
11. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, et al. (2010) Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 68: 193-203.
12. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R, (2008) Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 14: 1220-1224.
13. Stewart N, Simpson S Jr., van der Mei I, Ponsonby AL, Blizzard L, et al. (2012) Interferon-beta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology.
14. Lunemann JD, Tintore M, Messmer B, Strowig T, Rovira A, et al. (2010) Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 67: 159-169.
15. Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, et al. (2008) Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 14: 1026-1030.
16. Sundstrom P, Nystrom L, Hallmans G, (2008) Smoke exposure increases the risk for multiple sclerosis. Eur J Neurol 15: 579-583.
17. Vineis P, Airoldi L, Veglia F, Olgiati L, Pastorelli R, et al. (2005) Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 330: 277.
18. Duan X, Weinstock-Guttman B, Wang H, Bang E, Li J, et al. (2010) Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem 82: 2488-2497.
19. Weinstock-Guttman B, Zivadinov R, Ramanathan M, (2011) Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci 311: 86-91.
20. (2010) Consensus Report. Dietary Reference Intakes for Calcium and Vitamin D. Food and Nutrition Board. Institute of Nutrition.
21. Weinstock-Guttman B, Zivadinov R, Cutter G, Tamano-Blanco M, Marr K, et al. (2011) Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. PLoS One 6: e16802.
22. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, et al. (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57: 1239-1247.
23. Zivadinov R, Heininen-Brown M, Schirda CV, Poloni GU, Bergsland N, et al. (2012) Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 59: 331-339.
24. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, et al. (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17: 479-489.
25. Ingram G, Bugert JJ, Loveless S, Robertson NP, (2010) Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur J Neurol 17: 1386-1389.
26. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
27. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, et al. (2009) Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 132: 250-259.
28. Weatherby SJ, Thomson W, Pepper L, Donn R, Worthington J, et al. (2001) HLA-DRB1 and disease outcome in multiple sclerosis. J Neurol 248: 304-310.
29. Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, et al. (2002) HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 72: 184-187.
30. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, et al. (2000) Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 178: 132-135.
31. Weinshenker BG, Santrach P, Bissonet AS, McDonnell SK, Schaid D, et al. (1998) Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 51: 742-747.
32. Knoblach T, Grandel B, Seiler J, Nevels M, Paulus C, (2011) Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-gamma. PLoS Pathog 7: e1002016.
33. Arcenas R, Widen RH, (2002) Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus. BMC Microbiol 2: 20.
34. Saghafian-Hedengren S, Sundstrom Y, Sohlberg E, Nilsson C, Linde A, et al. (2009) Herpesvirus seropositivity in childhood associates with decreased monocyte-induced NK cell IFN-gamma production. J Immunol 182: 2511-2517.
35. Aalto SM, Linnavuori K, Peltola H, Vuori E, Weissbrich B, et al. (1998) Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 56: 186-191.
36. Singh N, (2005) Interactions between viruses in transplant recipients. Clin Infect Dis 40: 430-436.
37. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69: 292-302.